NEW ZEALAND DATA SHEET

1. PRODUCT NAME

Arrow-Lattim

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each mL contains latanoprost 50 micrograms and timolol 5 mg (equivalent to 6.83 mg timolol maleate).

Excipient of known effect: benzalkonium chloride

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Eye drops, solution. The solution is a clear, colourless liquid, filled in a polyethylene container.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Reduction of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension who are insufficiently responsive to beta-blockers, prostaglandins or other intraocular pressure lowering medications. Arrow-Lattim should not be used to initiate therapy.

4.2 Dose and method of administration

Dose

Adults (including elderly)

Recommended therapy is one eye drop in the affected eye(s) once daily. If one dose is missed, treatment should continue with the next dose as normal.

The use of Arrow-Lattim may be considered in patients who require both timolol and latanoprost, but it is unknown whether patients who are adequately controlled with timolol given twice daily plus latanoprost given once daily will be as well controlled with Arrow-Lattim given once daily. Arrow-Lattim should not be used to initiate therapy.

Arrow-Lattim should not be given more than once daily because latanoprost is most effective at this dosage. If there is inadequate response to Arrow-Lattim, consideration should be given to using the individual agents with timolol dose twice daily.

Paediatric population

The safety and efficacy of Arrow-Lattim in children and adolescents has not been established.

Method of administration

If more than one topical ophthalmic drug is being used, the eye drop products should be administered at least 5 minutes apart.

Systemic absorption can be minimised by pressure on the tear duct immediately after application of the eye drop.

Use with contact lenses: The contact lenses should be removed before instillation of the eye drops and may be reinserted after 15 minutes (see section 4.4 Special warnings and precautions for use).

4.3 Contraindications

- Reactive airway disease including bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease.
- Sinus bradycardia, sick sinus syndrome, sino-atrial block, second or third degree atrioventricular block not controlled with a pace-maker, overt cardiac failure, or cardiogenic shock.

• Known hypersensitivity to any component in Arrow-Lattim.

4.4 Special warnings and precautions for use

Systemic effects

Cardiovascular/respiratory reactions

Like other topically applied ophthalmic agents, Arrow-Lattim eye drops is absorbed systemically. Due to the beta-adrenergic component timolol, the same types of cardiovascular, pulmonary and other adverse reactions as seen with systemic beta-adrenergic blocking agents may occur.

Incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration. To reduce the systemic absorption, see section 4.2 Dose and method of administration.

In patients with cardiovascular diseases (eg. coronary heart disease, Prinzmetal's angina and cardiac failure) and hypotension therapy with beta blockers should be critically assessed and the therapy with other active substances should be considered. Patients with cardiovascular diseases should be watched for signs of deterioration of these diseases and of adverse reactions.

Due to its negative effect on conduction time, beta-blockers should only be given with caution to patients with first degree heart block. Cardiac reactions, and rarely, death in association with cardiac failures have been reported following administration of timolol.

Respiratory reactions, including death due to bronchospasm in patients with asthma have been reported following administration of some ophthalmic beta-blockers. Arrow-Lattim eye drops should be used with caution in patients with mild/moderate chronic obstructive pulmonary disease (COPD) and only if the potential benefit outweighs the potential risk.

Vascular disorders

Patients with severe peripheral circulatory disturbance/disorders (i.e. severe forms of Raynaud's disease or Raynaud's syndrome) should be treated with caution.

Hypoglycaemia/diabetes

Beta-blockers should be administered with caution in patients subject to spontaneous hypoglycaemia or to patients with labile diabetes, as beta-blockers may mask the signs and symptoms of acute hypoglycaemia. Beta-blockers may also mask the signs of hyperthyroidism.

Corneal diseases

Ophthalmic beta-blockers may induce dryness of eyes. Patients with corneal diseases should be treated with caution.

Other beta-blocking agents

The effect on intra-ocular pressure or the known effects of systemic beta-blockade may be potentiated when timolol is given to the patients already receiving a systemic beta-blocking agent. The response of these patients should be closely observed. The use of two topical betaadrenergic blocking agents is not recommended (see section 4.5 Interaction with other medicines and other forms of interaction).

Anaphylactic reactions

While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge with such allergens and unresponsive to the usual doses of adrenaline used to treat anaphylactic reactions.

Choroidal detachment

Choroidal detachment has been reported with administration of aqueous suppressant therapy (eg. timolol, acetazolamide) after filtration procedures.

Surgical anaesthesia

Beta-blocking ophthalmological preparations may block systemic beta-agonist effects e.g. of adrenaline. The anaesthesiologist should be informed when the patient is receiving timolol.

Concomitant therapy

Timolol may interact with other drugs (see section 4.5 Interaction with other medicines and other forms of interaction). The use of two local beta-blockers or two local prostaglandins is not recommended.

Ocular effects

Before treatment is initiated, patients should be informed of the possibility of prostaglandin analogue periorbitopathy (PAP) and increased iris pigmentation, since these have been observed during treatment with ocular prostaglandin analogues. Some of these changes may be permanent, and may lead to impaired field of vision and differences in appearance between the eyes when only one eye is treated (see section 4.8).

Latanoprost may gradually change eye colour by increasing the amount of brown pigment in the iris. Similar to experience with latanoprost eye drops, increased iris pigmentation was seen in 16-20% of all patients treated with latanoprost/timolol eye drops for up to one year (based on photographs).

This effect has predominantly been seen in patients with mixed coloured irides, i.e. green-brown, yellow brown or blue/grey-brown, and is due to increased melanin content in the stromal melanocytes of the iris. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery in affected eyes, but the entire iris or parts of it may become more brownish. In patients with homogeneously blue, grey, green or brown eyes, the change has only rarely been seen during two years of treatment in clinical trials with latanoprost.

The change in iris colour occurs slowly and may not be noticeable for several months to years and it has not been associated with any symptom or pathological changes.

No further increase in brown iris pigment has been observed after discontinuation of treatment, but the resultant colour change may be permanent. Neither naevi nor freckles of the iris have been affected by the treatment.

Accumulation of pigment in the trabecular meshwork or elsewhere in the anterior chamber has not been observed but patients should be examined regularly and, depending on the clinical situation, treatment may be stopped if increased iris pigmentation ensues.

Before treatment is instituted patients should be informed of the possibility of a change in eye colour. Unilateral treatment can result in permanent heterochromia.

Eyelid and eyelash changes

Eyelid skin darkening, which may be reversible, has been reported in association with the use of latanoprost.

Latanoprost may gradually change eyelashes and vellus hair in the treated eye; these changes include increased length, thickness, pigmentation, and number of lashes or hairs, and misdirected growth of eyelashes. Eyelash changes are reversible upon discontinuation of treatment.

Glaucoma

There is no documented experience with latanoprost in inflammatory, neovascular, or chronic angle closure glaucoma, in open angle glaucoma of pseudophakic patients and in pigmentary glaucoma. Latanoprost has no or little effect on the pupil but there is no documented experience in acute attacks of closed angle glaucoma. Therefore it is recommended that Arrow–Lattim eye drops should be used with caution in these conditions until more experience is obtained.

Herpetic keratitis

Latanoprost should be used with caution in patients with a history of herpetic keratitis, and should be avoided in cases of active herpes simplex keratitis and in patients with a history of recurrent herpetic keratitis specifically associated with prostaglandin analogues.

Macular oedema

Macular oedema, including cystoid macular oedema, has been reported during treatment with latanoprost. These reports have mainly occurred in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular oedema. Arrow-Lattim eye drops should be used with caution in these patients.

Use of contact lenses

Arrow-Lattim eye drops contain benzalkonium chloride, which is commonly used as a preservative in ophthalmic products. Benzalkonium chloride has been reported to cause punctuate keratopathy and/or toxic ulcerative keratopathy, may cause eye irritation.

Close monitoring is required with frequent or prolonged use of Arrow-Lattim eye drops in dry eye patients, or in conditions where the cornea is compromised.

Contact lenses may absorb benzalkonium chloride which is known to discolour soft contact lenses. Contact lenses should be removed before applying Arrow-Lattim eye drops but may be reinserted after 15 minutes (see section 4.2 Dose and method of administration).

4.5 Interaction with other medicines and other forms of interaction

No specific drug interaction studies have been performed with latanoprost/timolol eye drops.

There have been reports of paradoxical elevations in intraocular pressure following the concomitant ophthalmic administration of two prostaglandin analogues.

Therefore, the use of two or more prostaglandins, prostaglandin analogues, or prostaglandin derivatives is not recommended.

There is a potential for additive effects resulting in hypotension and/or marked bradycardia when ophthalmic beta-blockers solution is administered concomitantly with oral calcium channel blockers, beta-adrenergic blocking agents, antiarrhythmics (including amiodarone), digitalis glycosides, parasympathomimetics, guanethidine.

Potentiated systemic beta blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g. quinidine, fluoxetine, paroxetine) and timolol.

The effect on intraocular pressure or the known effects of systemic beta-blockade may be potentiated when Arrow-Lattim eye drops is given to patients already receiving an oral beta-adrenergic blocking agent, and the use of two or more topical beta-adrenergic blocking agents is not recommended.

Mydriasis resulting from concomitant use of ophthalmic beta-blockers and adrenaline (epinephrine) has been reported occasionally.

The hypertensive reaction to sudden withdrawal of clonidine can be potentiated when taking betablockers.

Beta-blockers may increase the hypoglycaemic effect of anti-diabetic agents. Betablockers can mask the signs and symptoms of hypoglycaemia (see section 4.4 Special warnings and precautions for use).

4.6 Fertility, pregnancy and lactation

Pregnancy

Use in pregnancy (category C)

There are no adequate data from the use of latanoprost in pregnant women. Studies in animals have shown reproductive toxicity (see **section 5.3 Preclinical safety data**). The potential risk for humans is unknown.

There are no adequate data from the use of timolol in pregnant women. Timolol should not be used during pregnancy unless clearly necessary. To reduce the systemic absorption, see section 4.2.

Epidemiological studies have not revealed malformative effects but show a risk for intra uterine growth retardation when beta-blockers are administered by the oral route. In addition, signs and symptoms of beta-blockade (eg. bradycardia, hypotension, respiratory distress and hypoglycaemia) have been observed in the neonate when beta-blockers have been administered until delivery. If Arrow-Lattim is administered until delivery, the neonate should be carefully monitored during the first days of life. Consequently, Arrow-Lattim should not be used during pregnancy (see section 5.3 Preclinical safety data).

Lactation

Beta-blockers are excreted in breast milk. However, at therapeutic doses of timolol in eye drops it is not likely that sufficient amounts would be present in breast milk to produce clinical symptoms of beta-blockade in the infant. To reduce the systemic absorption, see section 4.2.

Latanoprost and its metabolites may pass into breast milk. Arrow-Lattim should therefore not be used in women who are breast-feeding.

Fertility

Neither latanoprost nor timolol have been found to have any effect on male or female fertility in animal studies.

4.7 Effects on ability to drive and use machines

Arrow-Lattim has minor influence on the ability to drive and use machines. In common with other eye preparations, installation of eye drops may cause transient blurring of vision. Until this has resolved, patients should not drive or use machines.

4.8 Undesirable effects

For latanoprost, the majority of adverse reactions relate to the ocular system. In data from the extension phase of the latanoprost/timolol pivotal trials, 16 - 20% of patients developed increased iris pigmentation, which may be permanent. In an open 5 year latanoprost safety study, 33% of patients developed iris pigmentation (see section 4.4 Special warnings and precautions for use). Other ocular adverse reactions are generally transient and occur on dose administration.

For timolol, the most serious adverse reactions are systemic in nature, including bradycardia, arrhythmia, congestive heart failure, bronchospasm and allergic reactions.

Like other topically applied ophthalmic drugs, timolol is absorbed into the systemic circulation. This may cause similar undesirable effects as seen with systemic beta blocking agents. Incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration. Listed adverse reactions include reactions seen within the class of ophthalmic beta-blockers.

Treatment related adverse reactions seen in clinical trials with latanoprost/timolol eye drops are listed below.

Adverse reactions are categorized by frequency as follows: very common ($\geq 1/10$), common ($\geq 1/100$ to <1/10), uncommon ($\geq 1/1000$ to <1/100), rare ($\geq 1/10,000$ to <1/1000) and very rare (<1/10,000), not known (frequency cannot be estimated from the available data).

System Organ Class	Very common (≥1/10)	Common (≥1/100 to <1/10)	Uncommon (≥1/1,000 to < 1/100)
Nervous system disorders			Headache
Eye disorders	Iris hyperpigmentation	Eye pain, eye irritation (including stinging, burning, itching, foreign body sensation)	Corneal disorders, conjunctivitis, blepharitis, eye hyperaemia, vision blurred, lacrimation increased
Skin and subcutaneous tissue disorders			Rash, pruritus

Table 1: Adverse events from clinical trials

Additional adverse reactions have been reported specific to the use of the individual components of latanoprost/timolol eye drops in either clinical studies, spontaneous reports or in the available literature.

For latanoprost, these are:

Adverse Reaction Table 2: Latanoprost			
System Organ Class	Adverse Reactions		
Infections and infestations	Herpetic keratitis		
Nervous system disorders	Dizziness		
Eye disorders	Eyelash and vellus hair changes of the eyelid (increased		
	length, thickness, pigmentation, and number of		
	eyelashes); punctate keratitis, periorbital oedema; iritis;		
	uveitis; macular oedema including cystoid macular		
	oedema dry eye; keratitis; corneal oedema; corneal		
	erosion; trichiasis; iris cyst; photophobia; prostaglandin		
	analogue periorbitopathy; eyelid oedema; localised skin		
	reaction on the eyelids; pseudopemphigoid of the ocular		
	conjunctiva ⁺ ; darkening of the palpebral skin		
Cardiac disorders	Angina, angina unstable, palpitations		
Respiratory, thoracic and mediastinal	Asthma, asthma aggravation, dyspnoea		
disorders			
Gastrointestinal disorders	Nausea*; vomiting*		
Musculoskeletal and connective tissue	Myalgia, arthralgia		
disorders			
General disorders and administration site	Chest pain		
conditions			

* Identified post marketing with an estimated frequency of uncommon

⁺ may be potentially related to the preservative benzalkonium chloride

For timolol, these are:

Adverse Reaction Table 3: Timolol Male System Organ Class	Adverse Reactions	
Immune system disorders	Systemic allergic reactions including anaphylactic reaction, angioedema, urticaria, localised and generalised	
	rash, pruritus	
Metabolism and nutrition disorders	Hypoglycaemia	
Psychiatric disorders	Memory loss, insomnia, depression, nightmares, hallucinations	
Nervous system disorders	Cerebrovascular accident, cerebral ischaemia, dizziness, increases in signs and symptoms of myasthenia gravis, paraesthesia, headache, syncope	
Eye disorders	Choroidal detachment following filtration surgery (see section 4.4), corneal erosion, keratitis, diplopia, decreased corneal sensitivity, signs and symptoms of ocular irritation (e.g., burning, stinging, itching, tearing and redness), dry eyes, ptosis, blepharitis, blurred vision	
Ear and labyrinth disorders	Tinnitus	
Cardiac disorders	Cardiac arrest, cardiac failure, atrioventricular block, congestive heart failure, chest pain, arrhythmia, bradycardia, oedema, palpitations	
Vascular disorders	Cold hands and feet, hypotension, Raynaud's phenomenon	
Respiratory, thoracic and mediastinal disorders	Bronchospasm (predominately in patients with pre- existing bronchospastic disease), cough, dyspnoea	
Gastrointestinal disorders	Abdominal pain, vomiting, diarrhoea, dry mouth, dysgeusia, dyspepsia, nausea	
Skin and subcutaneous tissue disorders	Skin rash, psoriasiform rash, exacerbation of psoriasis, alopecia	
Musculoskeletal and connective tissue disorders	Myalgia	
Reproductive system and breast disorders	Sexual dysfunction, decreased libido	
General disorders and administration site conditions	Asthenia, fatigue	

Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged corneas.

Description of selected adverse reactions

Prostaglandin analogue periorbitopathy (PAP)

Prostaglandin analogues can induce periorbital lipodystrophic changes which can lead to deepening of the eyelid sulcus, ptosis, enophthalmos, eyelid retraction, involution of dermatochalasis and inferior scleral show. Changes are typically mild, can occur as early as one month after initiation of treatment, and may cause impaired field of vision even in the absence of patient recognition. PAP is also associated with periocular skin hyperpigmentation or discoloration and hypertrichosis. All changes have been noted to be partially or fully reversible upon discontinuation or switch to alternative treatments.

Iris hyperpigmentation

Increased iris pigmentation is likely to be permanent. The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. The long-term effects of increased iris pigmentation are not known. Iris colour changes seen with ophthalmic administration of ocular prostaglandin analogues may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts become more brownish. Neither naevi nor freckles of the iris appear to be affected by the treatment.

Reporting of suspected adverse reactions:

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions (https://nzphvc.otago.ac.nz/reporting/).

4.9 Overdose

No data are available in humans with regard to overdose with latanoprost/timolol eye drops.

Symptoms

Symptoms of systemic timolol overdose are: bradycardia, hypotension, bronchospasm and cardiac arrest.

Apart from ocular irriation and conjunctival hyperaemia, no other ocular and systemic side effects are known if latanoprost is overdosed.

Treatment

If symptoms of overdose occur the treatment should be symptomatic and supportive.

If accidentally ingested orally the following information may be useful:

Studies have shown that timolol does not dialyse readily. Gastric lavage if needed. Latanoprost is extensively metabolised during the first pass through the liver. Intravenous infusion of 3 micrograms/kg in healthy volunteers induced no symptoms, but a dose of 5.5-10 micrograms/kg caused nausea, abdominal pain, dizziness, fatigue, hot flushes and sweating. These events were mild to moderate in severity and resolved without treatment, within 4 hours after terminating the infusion.


For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Ophthalmological-betablocking agents - timolol, combinations, ATC code: S01ED51


Latanoprost



The chemical name of latanoprost is isopropyl-(Z)-7[(1R,2R,3R,5S) 3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenyl-1-pentyl]cyclopentyl]-5-heptenoate, according to IUPAC. Its molecular formula is $C_{26}H_{40}O_5$.

The CAS number for latanoprost is 130209-82-4.

Timolol maleate



The chemical name of timolol maleate is (S)-1-(*tert*-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Its molecular formula is $C_{13}H_{24}N_4O_3S \cdot C_4H_4O_4$.

The CAS number for timolol maleate is 26921-17-5.

The active ingredients in Arrow-Lattim eye drops are latanoprost and timolol maleate. Latanoprost is a prostaglandin $F_{2\alpha}$ analogue. It has a molecular weight of 432.58. It is a colourless to slightly yellow oil which is practically insoluble in water, freely soluble in ethanol, ethyl acetate, isopropanol, methanol, acetone and octanol, and very soluble in acetonitrile.

Sixty four isomers of latanoprost are possible however, for Arrow-Lattim it is purified as a single isomer. Timolol maleate is a beta-adrenergic receptor blocking agent. It has a molecular weight of 432.50. It is a white to off-white crystalline powder which is soluble in water, alcohol and practically insoluble in ether.

Mechanism of action

Arrow-Lattim consists of two components: latanoprost and timolol maleate. These two components decrease elevated intraocular pressure (IOP) by different mechanisms of action and the combined effect results in additional IOP reduction compared to either compound administered alone.

Latanoprost, a prostaglandin $F_{2\alpha}$ analogue, is a selective prostanoid FP receptor agonist that reduces the IOP by increasing the outflow of aqueous humour. The main mechanism of action is increased uveoscleral outflow. Additionally, some increase in outflow facility (decrease in trabecular outflow resistance) has been reported in man. Latanoprost has no significant effect on the production of aqueous humour, the blood-aqueous barrier or the intraocular blood circulation. Chronic treatment with latanoprost in monkey eyes, which had undergone extracapsular lens extraction did not affect the retinal blood vessels as determined by fluorescein angiography. Latanoprost has not induced fluorescein leakage in the posterior segment of pseudophakic human eyes during short term treatment.

Timolol is a beta-1 and beta-2 (non-selective) adrenergic receptor blocking agent that has no significant intrinsic sympathomimetic, direct myocardial depressant or membrane-stabilising activity. Timolol lowers IOP by decreasing the formation of aqueous in the ciliary epithelium.

The precise mechanism of action is not clearly established, but inhibition of the increased cyclic AMP synthesis caused by endogenous beta-adrenergic stimulation is probable. Timolol has not been found to significantly affect the permeability of the blood-aqueous barrier to plasma proteins. In rabbits, timolol was without effect on the regional ocular blood flow after chronic treatment.

Clinical Safety and Efficacy

In dose finding studies, latanoprost/timolol eye drops produced significantly greater decreases in mean diurnal IOP compared to latanoprost and timolol administered once daily as monotherapy. In two well controlled, double masked six-month clinical studies the IOP reducing effect of latanoprost/timolol combination was compared with latanoprost and timolol monotherapy in patients with an IOP of at least 25 mm Hg or greater. Following a 2-4 week run-in with timolol (mean decrease in IOP from enrollment of 5 mm Hg), additional decreases in mean diurnal IOP of 3.1, 2.0 and 0.6 mm Hg were observed after 6 months of treatment for latanoprost/timolol combination, latanoprost and timolol (twice daily), respectively. The IOP lowering effect of latanoprost/timolol eye drops was maintained in 6 month open label extension of these studies.

Existing data suggest that evening dosing may be more effective in IOP lowering than morning dosing. However, when considering a recommendation of either morning or evening dosing, sufficient consideration should be given to the lifestyle of the patient and their likely compliance.

It should be kept in mind that in case of insufficient efficacy of the fixed combination, results from studies indicate that the use of unfixed administration of timolol twice a day and latanoprost once a day might be still efficient.

Onset of action of latanoprost/timolol eye drops is within one hour and maximal effect occurs within six to eight hours. Adequate IOP reducing effect has been shown to be present up to 24 hours post dosage after multiple treatments.

5.2 Pharmacokinetic properties

Latanoprost

Latanoprost is an isopropyl ester pro-drug which is inactive, but after hydrolysis by esterases in the cornea to the acid of latanoprost, becomes biologically active.

The pro-drug is well absorbed through the cornea and all drug that enters the aqueous humour is hydrolysed during the passage through the cornea.

Studies in man indicate that the peak concentration in the aqueous humour, approximately 15-30 ng/mL, is reached about two hours after topical administration of latanoprost alone.

After topical application in monkeys, latanoprost is distributed primarily in the anterior segment, the conjunctivae and the eye lids.

The acid of latanoprost has a plasma clearance of 0.40 L/h/kg and a small volume of distribution, 0.16 L/kg, resulting in a rapid half-life in plasma of 17 minutes. After topical ocular administration the systemic bioavailability of the acid of latanoprost is 45%. The acid of latanoprost has a plasma protein binding of 87%.

There is practically no metabolism of the acid of latanoprost in the eye. The main metabolism occurs in the liver.

The main metabolites, the 1,2-dinor and 1, 2, 3, 4-tetranor metabolites, exert no or only weak biological activity in animal studies and are excreted primarily in the urine.

Timolol

The maximum concentration of timolol in the aqueous humour is reached about 1 hour after topical administration of eye drops. Part of the dose is absorbed systemically and a maximum plasma concentration of 1 ng/mL is reached 10-20 minutes after topical administration of one eye drop to each eye once daily (300 μ g/day). The half-life of timolol in plasma is about 6 hours. Timolol is extensively metabolised in the liver. The metabolites are excreted in urine together with some unchanged timolol.

Latanoprost/Timolol combination

No pharmacokinetic interactions between latanoprost and timolol have been observed although the aqueous humour concentrations of the acid of latanoprost tended to be higher 1 to 4 hours after administration of the combination product compared to monotherapy with either agent.

5.3 Preclinical safety data

The ocular and systemic safety profile of the individual components is well established. No adverse ocular or systemic effects were seen in rabbits treated topically with the fixed combination or with concomitantly administered latanoprost and timolol ophthalmic solutions. Safety pharmacology, genotoxicity and carcinogenicity studies with each of the components revealed no special hazards for humans. Latanoprost did not affect corneal wound healing in the rabbit eye, whereas timolol inhibited the process in the rabbit and the monkey eye when administered more frequently than once a day.

For latanoprost, no effects on male and female fertility in rats and no teratogenic potential in rats and rabbits have been established. No embryotoxicity was observed in rats after intravenous doses of up to 250 micrograms/kg/day. However, latanoprost caused embryofoetal toxicity, characterised by increased incidence of late resorption and abortion and by reduced foetal weight, in rabbits at intravenous doses of 5 micrograms/kg/day (approximately 100 times the clinical dose) and above. Timolol showed no effects on male and female fertility in rats or teratogenic potential in mice, rats and rabbits.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Benzalkonium chloride Sodium chloride Sodium dihydrogen phosphate monohydrate Disodium phosphate Hydrochloric acid (to adjust pH) Sodium hydroxide solution (to adjust pH) Water for Injections

6.2 Incompatibilities

In vitro studies have shown that precipitation occurs when eye drops containing thiomersal are mixed with Latanoprost eye drops. If such drugs are used concomitantly with Arrow-Lattim, the eye drops should be administered with an interval of at least five minutes.

6.3 Shelf life

Before first opening:2 yearsAfter first opening of bottle:4 weeks

6.4 Special precautions for storage

Unopened: Store in a refrigerator $(2^{\circ}C - 8^{\circ}C)$. Do not freeze. Keep the bottle in the outer carton in order to protect from light.

Version 1.2

After first opening the bottle: Do not store above 25°C and use within four weeks. Keep the bottle in the outer carton in order to protect from light.

6.5 Nature and contents of container

LDPE bottle (5 mL) with insert-cap assembly comprising of a yellow coloured screw cap over a LDPE nozzle with tamper-evident LDPE dustcover sealing the bottle cap.

Each 5 mL bottle contains 2.5 mL eye drop solution corresponding to a minimum of 80 drops of solution. One drop contains approximately 1.5 micrograms latanoprost and 150 micrograms timolol.

Pack sizes: 1 x 2.5 mL

6.6 Special precautions for disposal

The tamper evident dustcover should be removed before use. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MEDICINE SCHEDULE

Prescription Only Medicine

8. SPONSOR

Teva Pharma (New Zealand) Limited PO Box 128 244 Remuera Auckland 1541 Telephone: 0800 800 097

9. DATE OF FIRST APPROVAL

3 October 2013

10. DATE OF REVISION OF THE TEXT

18 April 2023

SUMMARY TABLE OF CHANGES

Section changed	Summary of new information	
4.8	Adverse reactions nausea and vomiting included.	